LONDON--(BUSINESS WIRE)--Veryan Medical has appointed healthcare business consultancy Pan Globus to help proctor the European clinical trial of its new BioMimics 3D™ stent technology. Proving the safety and efficacy of a new medical device in a timely and cost effective manner is vital if patients are to benefit from the new technology and Veryan Medical is to meet its business targets.
The Mimics study will see up to 90 patients across Germany receive either a BioMimics 3D™ stent or a control stent. Veryan turned to Pan Globus for an outsourcing solution that provided access to experienced clinical trials professionals at a fixed cost that also freed Veryan's management team to focus on the jobs they were hired to do.
Commenting on the agreement, Vanessa Lee, Proctor and Case Support Manager of Veryan Medical, said that “Pan Globus has provided us with an experienced and reliable clinical trials manager who has become well respected by the investigators taking part in the Mimics study. We need to ensure that the investigators and their research teams adhere to the protocol and complete all of the documentation to the highest standard. Overseeing that process requires a real eye for detail, a sound clinical knowledge and strong interpersonal skills.”
Robert MacPherson, Managing Director of Pan Globus, said, “No company should enter into a clinical trial unless it already knows the result and with some studies costing more than $50million, managing costs and ensuring that all of the data is captured are fundamental keys to success.
- ends -
EDITORS’ NOTES
Pan Globus was established in 2008, is headquartered in London and is the only global, business services company focused on the medical device industry. Pan Globus enables medical device companies to reduce the time required to bring new medical devices to market by optimising clinical trials, providing experienced temporary management teams and access to an established international sales and distribution network.